| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
154,660,000 |
| Market
Cap: |
184.05(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.429 - $1.75 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adaptimmune Therapeutics is a biopharmaceutical company focused on developing T-cell therapies for solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. Co. has clinical trials on its ADP-A2M4, ADP-A2M4CD8, each targeting the MAGE-A4 antigen, and ADP-A2AFP SPEAR T-cells targeting the alpha fetoprotein (AFP) cancer antigen in solid tumor types including non-small cell lung cancer, head and neck cancer, ovarian, urothelial, melanoma, and hepatocellular.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
39,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$11,326 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
165,799 |
218,930 |
354,372 |
| Total Sell Value |
$0 |
$124,385 |
$172,782 |
$411,912 |
| Total People Sold |
0 |
4 |
5 |
6 |
| Total Sell Transactions |
0 |
16 |
19 |
41 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lunger John |
Chief Patient Supply Officer |
• – – |
2021-01-19 |
4 |
S |
$5.67 |
$24,708 |
D/D |
(4,358) |
7,346 |
|
15% |
|
| Rawcliffe Adrian |
Chief Executive Officer |
• • – |
2021-01-19 |
4 |
S |
$5.67 |
$56,009 |
D/D |
(9,879) |
13,529 |
|
15% |
|
| Bertrand William C Jr |
Chief Operating Officer |
• – – |
2021-01-12 |
4 |
S |
$6.15 |
$13,744 |
D/D |
(2,234) |
3,768 |
|
14% |
|
| Lunger John |
Chief Patient Supply Officer |
• – – |
2021-01-12 |
4 |
S |
$6.15 |
$6,509 |
D/D |
(1,058) |
1,767 |
|
14% |
|
| Rawcliffe Adrian |
Chief Executive Officer |
• • – |
2021-01-12 |
4 |
S |
$6.15 |
$16,654 |
D/D |
(2,707) |
3,695 |
|
14% |
|
| Norry Elliot |
Chief Medical Officer |
• – – |
2021-01-12 |
4 |
S |
$6.15 |
$5,174 |
D/D |
(841) |
1,396 |
|
14% |
|
| Norry Elliot |
Chief Medical Officer |
• – – |
2021-01-04 |
4 |
S |
$5.33 |
$4,502 |
D/D |
(845) |
1,392 |
|
24% |
|
| Bertrand William C Jr |
Chief Operating Officer |
• – – |
2021-01-04 |
4 |
S |
$5.33 |
$18,642 |
D/D |
(3,499) |
5,864 |
|
24% |
|
| Rawcliffe Adrian |
Chief Executive Officer |
• • – |
2021-01-04 |
4 |
S |
$5.33 |
$26,464 |
D/D |
(4,967) |
6,737 |
|
24% |
|
| Lunger John |
Chief Patient Supply Officer |
• – – |
2021-01-04 |
4 |
S |
$5.33 |
$5,674 |
D/D |
(1,065) |
1,760 |
|
24% |
|
| Wood Gavin |
Chief Financial Officer |
• – – |
2020-12-14 |
4 |
B |
$0.69 |
$16,550 |
D/D |
24,000 |
57,000 |
2.74 |
37% |
|
| Bertrand William C Jr |
Chief Operating Officer |
• – – |
2020-12-14 |
4 |
B |
$0.69 |
$143,824 |
D/D |
207,000 |
284,808 |
2.74 |
37% |
|
| Rawcliffe Adrian |
Chief Executive Officer |
• • – |
2020-09-01 |
4 |
S |
$8.51 |
$23,637 |
D/D |
(2,776) |
3,076 |
|
32% |
|
| Tayton-Martin Helena Katrina |
Chief Business Officer |
• – – |
2020-08-03 |
4 |
AS |
$8.74 |
$1,748,180 |
D/D |
(200,000) |
0 |
|
-55% |
|
| Rawcliffe Adrian |
Chief Executive Officer |
• • – |
2020-08-03 |
4 |
S |
$9.25 |
$25,789 |
D/D |
(2,788) |
3,064 |
|
55% |
|
| Lunger John |
Chief Patient Supply Officer |
• – – |
2020-08-03 |
4 |
S |
$9.25 |
$44,613 |
D/D |
(4,823) |
8,066 |
|
55% |
|
| Wood Gavin |
Chief Financial Officer |
• – – |
2020-06-29 |
4 |
B |
$1.62 |
$53,460 |
D/D |
33,000 |
33,000 |
2.74 |
-44% |
|
| Alleva Lawrence M |
Director |
– • – |
2020-06-09 |
4 |
B |
$1.89 |
$24,381 |
I/I |
12,900 |
12,900 |
2.1 |
-52% |
|
| Noble James |
Director |
– • – |
2020-05-29 |
4 |
AS |
$9.33 |
$4,666,000 |
D/D |
(500,000) |
0 |
|
58% |
|
44 Records found
|
|
Page 2 of 2 |
|
|
0.04 (3.48%) 
